Molecular targeting in radiotherapy: epidermal growth factor receptor.
Radiation therapy is utilized as a treatment to cure or manage cancer; however, because of risk to local healthy tissue-and a modest success rate of some radiotherapy-strategies have been sought that would increase the therapeutic index of the treatment while reducing damage to surrounding tissue. Cell and tissue irradiation stimulates a series of biochemical and molecular signals; various components of this ionizing radiation (IR)-inducible signal transduction cascade can promote the survival of tumor cells. Identification of interactions between IR and a signaling pathway creates an opportunity to target those signaling intermediates to improve the outcome of radiotherapy. The epidermal growth factor receptor (EGFR, also termed ErbB1) is involved in normal development and differentiation of epithelial cells as well as in tumorigenesis. The EGFR is activated by IR, thus making this receptor and other members of the ErbB family important targets for radiosensitizing molecular interventions. Recent approaches have utilized monoclonal antibodies, small molecules, and transgenic technologies to undermine the kinase activity of EGFR.
Chung
Theodore D
TD
Department of Radiation Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA. tchung@hsc.vcu.edu
Broaddus
William C
WC
D000818:Animals; D066246:ErbB Receptors / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D017434:Protein Structure, Tertiary; D011836:Radiation Tolerance; D011839:Radiation, Ionizing; D015398:Signal Transduction
D066246:ErbB Receptors